Reviewing BioScrip (BIOS) and Its Competitors
BioScrip (NASDAQ: BIOS) is one of 15 public companies in the “Hospitals, Clinics & Primary Care Services” industry, but how does it weigh in compared to its peers? We will compare BioScrip to related businesses based on the strength of its analyst recommendations, profitability, dividends, risk, institutional ownership, earnings and valuation.
Earnings and Valuation
This table compares BioScrip and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|BioScrip||$935.59 million||-$41.50 million||-3.65|
|BioScrip Competitors||$1.06 billion||-$22.56 million||682.40|
BioScrip’s peers have higher revenue and earnings than BioScrip. BioScrip is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares BioScrip and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
BioScrip has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500. Comparatively, BioScrip’s peers have a beta of 1.58, indicating that their average share price is 58% more volatile than the S&P 500.
Institutional and Insider Ownership
83.6% of BioScrip shares are owned by institutional investors. Comparatively, 62.8% of shares of all “Hospitals, Clinics & Primary Care Services” companies are owned by institutional investors. 0.8% of BioScrip shares are owned by company insiders. Comparatively, 10.8% of shares of all “Hospitals, Clinics & Primary Care Services” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a breakdown of current recommendations and price targets for BioScrip and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioScrip presently has a consensus target price of $3.75, indicating a potential upside of 51.21%. As a group, “Hospitals, Clinics & Primary Care Services” companies have a potential upside of 30.96%. Given BioScrip’s stronger consensus rating and higher possible upside, research analysts plainly believe BioScrip is more favorable than its peers.
BioScrip peers beat BioScrip on 8 of the 12 factors compared.
BioScrip Company Profile
BioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient’s physician. The Company’s multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient’s specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.